Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05080075 · ClinicalTrials.gov registry record · Early Phase 1
Platelet Rich Plasma in Knee Osteoarthritis
A Early Phase 1 study, sponsored by University of Toledo Health Science Campus.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 33
- Enrollment target
NCT05080075: Completed Early Phase 1 study, sponsored by University of Toledo Health Science Campus.
NCT05080075 is a Early Phase 1 study that has completed, run by University of Toledo Health Science Campus. The registered enrollment target is 33 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (38% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05080075, a Early Phase 1 study, has completed, sponsored by University of Toledo Health Science Campus.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
In this study, the investigators will be performing intra-articular platelet rich plasma (PRP) injections for patients experiencing pain related to osteoarthritis of the knee. The investigators will be following clinical outcomes, and how they relate to concentrations of the PRP samples as well as following opioid and emergency room utilization pre and post-injection.
Primary Outcome
The investigators will have patients rate pain levels using the visual analog scale (VAS), which measures pain on a 1-10 point scale. A score of 10 indicates the highest level of pain. These will be performed on the day of the platelet rich plasma injection, shortly before the procedure is performed.
Interventions
- BIOLOGICAL Platelet Rich Plasma Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-12-02 |
| Est. Completion | 2023-11-06 |
| Phase | Early Phase 1 |
What the finished NCT05080075 record still lists
NCT05080075 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (38% lower).
The record links to 0 conditions, and to 1 intervention - of which Platelet Rich Plasma Injection is the first listed.
NCT05080075 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05080075 about?
NCT05080075 is a clinical study titled "Platelet Rich Plasma in Knee Osteoarthritis". In this study, the investigators will be performing intra-articular platelet rich plasma (PRP) injections for patients experiencing pain related to osteoarthritis of the knee. The investigators will be following clinical outcomes, and how they relate to concentrations of the PRP samples as well as f...
What is the current status of trial NCT05080075?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 33 participants. The study started on 2021-12-02. Estimated completion is 2023-11-06.
What interventions are being tested in trial NCT05080075?
The interventions under investigation include: Platelet Rich Plasma Injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT05080075?
This trial is sponsored by University of Toledo Health Science Campus, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05080075's enrollment target sits among peer trials
33 763rd of 2000 higher than 1,227 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI